Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

Here's Why You Should Add HAE Stock in Your Portfolio Now — Sep 26th, 2024

Haemonetics Corporation HAE is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability als...

Here's Why You Should Add HAE Stock in Your Portfolio Now — Sep 26th, 2024

Haemonetics Corporation HAE is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability als...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

Zacks Industry Outlook Highlights Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health — Sep 25th, 2024

For Immediate Release Chicago, IL – September 25, 2024 – Today, Zacks Equity Research discusses Boston Scientific BSX, Baxter International BAX, Haemonetics HAE and Phibro Animal Health PAHC. Industry: Medical Products Link: https://www.zacks.com/commentary/2340320/4-medical-product...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

HAE vs. BSX: Which Stock Is the Better Value Option? — Sep 27th, 2024

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great valu...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

HAE vs. BSX: Which Stock Is the Better Value Option? — Sep 27th, 2024

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great valu...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

Here's Why You Should Add HAE Stock in Your Portfolio Now — Sep 26th, 2024

Haemonetics Corporation HAE is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s Hemostasis Management franchise is evolving and helping create new opportunities for growth and diversification. Strong financial stability als...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

HAE vs. BSX: Which Stock Is the Better Value Option? — Sep 27th, 2024

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great valu...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

Is ResMed Stock a Smart Addition to Your Portfolio Right Now? — Oct 17th, 2024

ResMed Inc.’s RMD robust performance of its Mask business is supported by continued product development within the portfolio. Its Software-as-a-Service (SaaS) business continues to benefit from strategic buyouts. The company’s investment in digital health technology looks poised to dri...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

HAE or BSX: Which Is the Better Value Stock Right Now? — Oct 14th, 2024

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way to find great val...

HAE vs. BSX: Which Stock Is the Better Value Option? — Sep 27th, 2024

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best way to find great valu...

Haemonetics Corp (HAE) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges — Oct 9th, 2024

Revenue: $336 million, 8% growth on a reported basis, 3% organic growth. Adjusted Earnings Per Diluted Share: $1.02, a 3% decrease from the prior year. Plasma Revenue: Declined 3% in the first quarter. Hospital Revenue: Grew 31% on a reported basis, 13% organically. Adjusted Gross Margin: ...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024 — Oct 3rd, 2024

BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discu...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...

Robust Plasma Sales, New Innovations Aid Haemonetics Stock — Oct 8th, 2024

Haemonetics HAE has been banking on its growth drivers like the Plasma and Hospital business. New product launches also lead to market expansion. The stock carries a Zacks Rank #2 (Buy) currently. Major Factors Driving HAE Stock Haemonetics’ Plasma business continues to grow, banking o...